Currículo

Tiago-Torres_round
Prof. Doutor  Tiago Torres
Dermatologia

Licenciado em Medicina pela Faculdade de Medicina da Universidade do Porto.

Internato de Especialidade de Dermatologia no Serviço de Dermatologia do Centro Hospitalar do Porto.

Fellowship no Serviço de Dermatologia do Hospital Università degli Studi di Roma “Tor Vergata”, em Roma, na área da Psoríase e Artrite Psoriática.

Assistente Hospitalar de Dermatologia no Serviço de Dermatologia do Centro Hospitalar do Porto.

Responsável pela Consulta de Psoríase e pela Consulta de Dermatoses Auto-Imunes no Serviço de Dermatologia do Centro Hospitalar do Porto.

Responsável pela Unidade de Ensaios Clínicos do Serviço de Dermatologia do Centro Hospitalar do Porto – Investigador principal em mais de 10 ensaios clínicos de novas terapêuticas para a psoríase.

Responsável pela Unidade de Dermatologia do Instituto Médico de Estudos Imunológicos

Responsável pela Unidade de Diagnóstico e Tratamento de Cancro da Pele do Hospital Luz Arrábida e Hospital Luz Clínica do Porto.

Doutorado em Ciências Médicas pelo Instituto Ciências Biomédicas Abel Salazar da Universidade do Porto com a tese: “Psoríase como factor de risco de doença cardiovascular”.

Professor Auxiliar Convidado do Mestrado Integrado em Medicina do Instituto Ciências Biomédicas Abel Salazar da Universidade do Porto.

Orientador e Jurí de Teses de Mestrado de Alunos do Mestrado Integrado em Medicina do Instituto Ciências Biomédicas Abel Salazar da Universidade do Porto.

Responsável pela Unidade de Ensaios Clínicos do Serviço de Dermatologia do Centro Hospitalar do Porto – Investigador principal em mais de 10 ensaios clínicos de novas terapêuticas para a psoríase.

Membro da Unidade Multidisciplinar de Investigação Biomédica do Instituto Ciências Biomédicas Abel Salazar da Universidade do Porto.

Membro da Unidade de Investigação em Dermatologia do Centro Hospitalar do Porto.

Membro consultor da International Psoriasis Council.

Editor Associado da Acta Médica Portuguesa.

Editor Associado da Revista da Sociedade Portuguesa de Dermatologia e Venereologia.

Membro do Conselho Editorial do Livro “Therapeutics In Dermatology” da Fondation René Touraine.

Coordenador científico do “DermaOnline” – Formação médica contínua on-line em Dermatologia.

Membro do Conselho Editorial do “Wellspring” – Formação médica contínua on-line em Psoríase.

Membro da Comissão Científica para a elaboração da Norma Clínica da DGS “Tratamento da Psoríase com Agentes Biológicos em Idade não Pediátrica”.

Premiado com a Bolsa de Investigação Juvenal Esteves de 2010, 2013 e 2017 da Sociedade Portuguesa de Dermatologia e Venereologia com projectos de investigação na área da Psoríase e Artrite Psoriática.

Membro das Sociedade Científicas:

Sociedade Portuguesa de Dermatologia e Venereologia
European Academy of Dermatology and Venereology
European Society of Cutaneous Lupus Erythematosus
International Dermoscopy Society

Publicações em revistas científicas internacionais:

Torres T Selective Interleukin-23 p19 Inhibition: Another Game Changer in Psoriasis? Focus on Risankizumab. Drugs. 2017 Aug 2.

Torres T., Puig L. Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic Arthritis. Am J Clin Dermatol. 2017 Jun 8.

Torres T., Romanelli M, Chiricozzi A. A revolutionary therapeutic approach for psoriasis: bispecific biological agents. Expert Opin Investig Drugs. 2016 Jul;25(7):751-4.

Torres T., Raposo I, Selores M. IL-17 Blockade in Psoriasis: Friend or Foe in Cardiovascular Risk? Am J Clin Dermatol. 2016 Apr;17(2):107-12.

• Azevedo A, Torres T. Tofacitinib: A New Oral Therapy for Psoriasis. Clin Drug Investig. 2018 Feb;38(2):101-112.

• Machado Á, Torres T. Guselkumab for the Treatment of Psoriasis. BioDrugs. 2018 Feb 22.

• Ferreira S, Torres T. Dupilumab for the Treatment of Atopic Dermatitis. Actas Dermosifiliogr. 2018 Feb 5.

Torres T. Atopic Dermatitis: The New Therapeutic Revolution in Dermatology. Acta Med Port. 2017 Oct 31;30(10):669-670.

Torres T, Ferreira A, Ferreira P, Henriques M, Leite L, Magina S, Marques Pinto G, Oliveira H, Sousa Basto A, Tavares Bello R, Varela P, Massa A, Selores M, Filipe P. Portuguese Position Paper on the Use of Biosimilars in Psoriasis. Acta Med Port. 2016 Sep;29(9):574-577.

Torres T, Faria R. Ustekinumab: the “new kid on the block” in the treatment of psoriatic arthritis. Drug Dev Res. 2015 Dec;76(8):428-31.

Torres T, Filipe P. Small Molecules in the Treatment of Psoriasis. Drug Dev Res. 2015 Aug;76(5):215-27.

Torres T, Bettencourt N, Ferreira J, Carvalho C, Mendonça D, Vasconcelos C, Selores M, Silva B. Lack of association between leptin, leptin receptor, adiponectin gene polymorphisms and epicardial adipose tissue, abdominal visceral fat volume and atherosclerotic burden in psoriasis patients. Arch Physiol Biochem. 2015 Jul;121(3):103-8.

Torres T, Puig L. Treatment goals for psoriasis: Should PASI 90 become the standard of care? Actas Dermosifiliogr. 2015 Apr;106(3):155-7.

Torres T, Bettencourt N, Ferreira J, Carvalho C, Mendonça D, Pinho-Costa P, Vasconcelos C, Selores M, Silva B. Influence of IL-6 polymorphisms on epicardial adipose tissue and coronary artery calcification in psoriasis patients. Br J Dermatol. 2016 Jan;30(1):191-3.

Torres T, Bettencourt N, Ferreira J, Carvalho C, Mendonça D, Pinho-Costa P, Vasconcelos C, Selores M, Silva B. Influence of TNF- gene polymorphisms in coronary artery calcification in psoriasis patients. J Eur Acad Dermatol Venereol. 2015 Feb;172(2):534-6.

Torres T, Bettencourt N, Mendonça D, Vasconcelos C, Gama V, Silva BM, Selores M. Epicardial adipose tissue and coronary artery calcification in psoriasis patients. J Eur Acad Dermatol Venereol. 2015 Feb;29(2):270-7.

Torres T, Bettencourt N, Mendonça D, Vasconcelos C, Silva BM, Selores M. Complement C3 as a marker of cardiometabolic risk in psoriasis. Arch Dermatol Res. 2014 Sep;306(7):653-60.

Torres T, Filipe P. Interleukin-17 as a Therapeutic Target in Psoriasis. Acta Med Port. 2014 Mar-Abr;27(2):252-258.

Torres T, Machado S, Mendonça D, Selores M. Cardiovascular comorbidities in childhood psoriasis. Eur J Dermatol. 2014 Apr 1;24(2):229-35.

Torres T, Bettencourt N. Psoriasis: The visible killer. Rev Port Cardiol. 2014 Feb;33(2):95-9.

Torres T, Alexandre JM, Mendonça D, Vasconcelos C, Silva BM, Selores M. Levels of Physical Activity in Patients with Severe Psoriasis: A Cross-Sectional Questionnaire Study. Am J Clin Dermatol. 2014 Apr;15(2):129-35.

Torres T, Filipe P, Selores M. Impact of biosimilars in psoriasis treatment. Acta Med Port. 2013 Nov-Dec;26(6):646-8.

Torres T, Sales R, Vasconcelos C, Selores M. Psoriasis and cardiovascular disease. Acta Med Port. 2013 Sep-Oct;26(5):601-7.

Torres T, Sales R, Vasconcelos C, Martins Silva B, Selores M. Framingham Risk Score under-estimates cardiovascular risk in severe psoriasis patients – implications in cardiovascular risk factors management and primary prevention of cardiovascular disease. J Dermatol. 2013 Nov;40(11):923-6.

Torres T, Chiricozzi A, Chimenti S, Saraceno R. Genetic Markers for Cardiovascular Disease in Psoriasis: The Missing Piece. Mol Diagn Ther. 2014 Feb;18(1):93-5.

Torres T, Vilaça S, Velho G, Selores M. Etanercept-induced asthma in a psoriatic patient resolving with transition to ustekinumab. Eur J Dermatol. 2012 Sep-Oct;22(5):696-7.

Torres T, Selores M. Does treatment of metabolic syndrome components improve psoriasis? Report of three cases. Eur J Dermatol. 2012 Mar-Apr;22(2):270-2.

Torres T, Fernandes I, Selores M, Alves R, Lima M. Aprepitant: Evidence of its effectiveness in patients with refractory pruritus continues. J Am Acad Dermatol. 2012 Jan;66(1):e14-5.

• Queirós N, Torres T.HIV-Associated Psoriasis. Actas Dermosifiliogr. 2018 Jan 17.

• Matos R, Torres T. Photo Quis – Koebner Phenomenon. Am Fam Physician. 2017 Nov 1;96(9):603-604.

• Raposo I, Carvalho C, Bettencourt A, Martins B, Leite L, Selores S, Torres T. Psoriasis pharmacogenetics: HLA-Cw*0602 as a marker of therapeutic response to Ustekinumab. Eur J Dermatol. Eur J Dermatol. 2017 Oct 1;27(5):528-530.

• Pereira R, Lago P, Faria R, Nery F, Torres T. Risk of Hepatits B virus reactivation in patients treated with anti-TNFα agents for Immune-mediated inflammatory diseases. Actas Dermosifiliogr. Actas Dermosifiliogr. 2017 Oct 17.

• Raposo I, Bettencourt A, Selores M, Torres T. Awareness and screening attitudes of Portuguese dermatologists on cardiovascular risk factors in psoriatic patients. Eur J Dermatol. 2017 Aug 1;27(4):443-445.

• Ferreira M, Barreiros L, Segundo MA, Torres T, Selores M, Costa Lima SA, Reis S. Topical co-delivery of methotrexate and etanercept using lipid nanoparticles: A targeted approach for psoriasis management. Colloids Surf B Biointerfaces. 2017 Jul 29;159:23-29.

• Mota F, Neves E, Oliveira JC, Selores M, Torres T. Importance of immunogenicity testing for cost-effective management of psoriasis patients treated with adalimumab. Acta Dermatovenerol Alp Pannonica Adriat. 2017 Jun;26(2):33-35.

• Pereira R, Faria R, Lago P, Torres T. Infection and Malignancy Risk in Patients Treated with TNF Inhibitors for Immune-Mediated Inflammatory Diseases. Curr Drug Saf. 2017 Jun 15.

• Relvas M, Torres T. Pediatric Psoriasis. Am J Clin Dermatol. 2017 May 24.

• Azevedo A, Torres T. Clinical Efficacy and Safety of Ixekizumab for Treatment of Psoriasis. Actas Dermosifiliogr. 2017 May;108(4):305-314.

• Azevedo A, Gonçalves C, Selores M, Torres T. Remission of psoriasis after autologous stem cell transplantation – until when? Eur J Dermatol. 2017 Feb 1;27(1):74-75.

• Matos RS, Torres T. Facial hair growth in a patient with psoriasis. Aust Fam Physician. 2016 Sep;45(9):641-2.

• Chiricozzi A, Romanelli M, Saraceno R, Torres T. No meaningful association between suicidal behavior and the use of IL-17A-neutralizing or IL-17RA-blocking agents. Expert Opin Drug Saf. 2016 Dec;15(12):1653-1659.

• Ferreira da Silva C, Torres T. Development of erythematous scaly lesions in a cervical surgical scar. Aust Fam Physician. 2016 May;45(5):310-1.

• Raposo I, Torres T. Palmoplantar Psoriasis and Palmoplantar Pustulosis: Current Treatment and Future Prospects. Am J Clin Dermatol. 2016 Aug;17(4):349-58.

• Tendais-Almeida J, Fátima Aguiar F, Torres T. Nail pitting and onycholysis. Aust Fam Physician. 2016 Mar;45(3):120-1.

• Mota F, Selores M, Torres T. Importance of educational sessions on cardiometabolic comorbidities. Awareness among psoriasis patients. Actas Dermosifiliogr. 2016 Jul-Aug;107(6):539-41.

• Teixeira A, Teixeira M, Almeida V, Torres T, Sousa Lobo JM, Almeida IF. Methodologies for medication adherence evaluation: Focus on psoriasis topical treatment. J Dermatol Sci. 2016 May;82(2):63-8.

• Bettencourt A, Carvalho C, Leal B, Brás S, Lopes D, Martins da Silva A, Santos E, Torres T, Almeida I, Farinha F, Barbosa P, Marinho A, Selores M, Correia J, Vasconcelos C, Costa PP, da Silva BM. The Protective Role of HLA-DRB1(∗)13 in Autoimmune Diseases. J Immunol Res. 2015;2015:948723.

• Rafael A, Torres T. Topical therapy for psoriasis: a promising future. Focus on JAK and phosphodiesterase-4 inhibitors. Eur J Dermatol. 2016 Jan-Feb;26(1):3-8.

• Pereira R, Lago P, Faria R, Torres T. Safety of Anti-TNF Therapies in Immune-Mediated Inflammatory Diseases: Focus on Infections and Malignancy. Drug Dev Res. 2015 Dec;76(8):419-27.

• Raposo I, Torres T. Psoriasis strikes back! Epicardial adipose tissue: Another contributor to the higher cardiovascular risk in psoriasis. Rev Port Cardiol. 2015 Oct;34(10):613-6.

• Raposo I, Torres T. Nail psoriasis as a predictor of the development of psoriatic arthritis. Actas Dermosifiliogr. 2015 Jul-Aug;106(6):452-7.

• Correia B, Torres T. Obesity: a key component of psoriasis. Acta Biomed (in press).

• Cabete J*, Torres T, Vilarinho T, Ferreira A, Selores M. Erectile dysfunction in psoriasis patients. Eur J Dermatol 2014 Jul-Aug;24(4):482-6.

• Sales R, Torres T. Psoriasis and metabolic syndrome. Acta Dermatovenerol Croat 2014;22(3):169-74.

• Pinto-Almeida T, Torres T. Biologic therapy for psoriasis – still searching for the best target. An Bras Dermatol. 2014 Apr;89(2):365-7.

• Samões R, Carvalho S, Alves R, Torres T, Silva AM. Ischemic skin necrosis caused by glatiramer acetate in multiple sclerosis patients. Eur J Dermatol. 2014 Apr 22.

• Papoutsaki M, Osório F, Morais P, Torres T, Magina S, Chimenti S, Costanzo A. Infliximab in psoriasis and psoriatic arthritis. BioDrugs. 2013 Jan;27 Suppl 1:13-23.

• Pinto-Almeida T, Torres T Selores M. Multiple myeloma in a patient under ustekinumab – are they related? Eur J Dermatol. 2013 Aug 1;23(4):567-8.

• Fernandes IC, Torres T, Selores M. Maintenance treatment of psoriasis with cyclosporine A: comparison between continuous and weekend therapy. J Am Acad Dermatol. 2013 Feb;68(2):341-2.

• Saraceno R, Specchio F, Torres T, Nisticò SP, Rizza S, Chimenti S. The role of antinuclear autoantibodies in patients with psoriasis treated with anti-tumor necrosis factor-alpha agents: a retrospective long-term study. J Am Acad Dermatol. 2012 May;66(5):e180-2.

Torres T, Vilaça S, Velho G, Selores M. Etanercept-induced asthma in a psoriatic patient resolving with transition to ustekinumab. Eur J Dermatol. 2012 Sep-Oct;22(5):696-7.

• Fernandes IC, Torres T, Sanches M, Velho G, Lago P, Selores M. [Psoriasis induced by infliximab]. Acta Med Port. 2011 Dec;24 Suppl 3:709-12.

Torres T, Velho GC, Sanches M, Selores M. [Psoriasis in the era of biologics]. Acta Med Port. 2010 May-Jun;23(3):493-8.